Natixis’s AbbVie ABBV Stock Holding History

Natixis’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-348	Closed	-$47K	–	1070
2022 Q3	$47K	Buy	348 +12	+4%	+$1.72K	﹤0.01%	1009
2022 Q2	$51K	Buy	+336	New	+$51.3K	﹤0.01%	1072

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Natixis's ABBV Position: Q2 2026 in Review

Natixis increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $7.28M and bringing the position to 267,055 shares worth $67.2M. The position accounts for 0.27% of the portfolio, ranked #53.

Natixis first reported a position in ABBV in Q2 2013 and has held it in 50 quarters since. The position peaked at $199M in Q3 2018. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Natixis held 267,055 shares of AbbVie worth $67.2M as of Q2 2026.
Natixis bought 33,859 AbbVie shares in Q2 2026, an estimated $7.28M.
AbbVie made up 0.27% of Natixis's portfolio in Q2 2026, its #53 holding.
Natixis first reported a position in AbbVie in Q2 2013 and has held it in 50 quarters since.
Natixis's AbbVie position peaked at $199M in Q3 2018.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.